Argent Trust Co bought a new stake in Globus Medical, Inc. (NYSE:GMED – Get Rating) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,698 shares of the medical device company’s stock, valued at approximately $200,000.
Other institutional investors also recently made changes to their positions in the company. Ronald Blue Trust Inc. raised its position in shares of Globus Medical by 160.1% during the 4th quarter. Ronald Blue Trust Inc. now owns 450 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 277 shares in the last quarter. Benjamin Edwards Inc. raised its position in shares of Globus Medical by 51.9% during the 4th quarter. Benjamin Edwards Inc. now owns 439 shares of the medical device company’s stock valued at $33,000 after acquiring an additional 150 shares in the last quarter. Signaturefd LLC raised its position in shares of Globus Medical by 192.9% during the 3rd quarter. Signaturefd LLC now owns 820 shares of the medical device company’s stock valued at $49,000 after acquiring an additional 540 shares in the last quarter. Covestor Ltd raised its position in shares of Globus Medical by 86.5% during the 1st quarter. Covestor Ltd now owns 785 shares of the medical device company’s stock valued at $58,000 after acquiring an additional 364 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Globus Medical during the 3rd quarter valued at approximately $60,000. 74.23% of the stock is owned by institutional investors and hedge funds.
In other news, Director Dan Lemaitre sold 43,450 shares of the company’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $56.98, for a total value of $2,475,781.00. Following the completion of the sale, the director now owns 10,800 shares in the company, valued at $615,384. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 24.41% of the company’s stock.
Analyst Ratings Changes
Globus Medical Stock Down 0.6 %
Shares of Globus Medical stock opened at $53.07 on Friday. The firm has a market cap of $5.32 billion, a price-to-earnings ratio of 26.94, a price-to-earnings-growth ratio of 1.81 and a beta of 1.06. The business has a fifty day simple moving average of $56.32 and a 200-day simple moving average of $64.35. Globus Medical, Inc. has a fifty-two week low of $50.92 and a fifty-two week high of $80.04.
Globus Medical (NYSE:GMED – Get Rating) last announced its quarterly earnings data on Thursday, May 4th. The medical device company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.02. The business had revenue of $276.90 million during the quarter, compared to analyst estimates of $254.05 million. Globus Medical had a return on equity of 12.26% and a net margin of 18.82%. The company’s revenue was up 20.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.42 earnings per share. Analysts anticipate that Globus Medical, Inc. will post 2.32 earnings per share for the current fiscal year.
Globus Medical Profile
Globus Medical, Inc operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments.
- Get a free copy of the StockNews.com research report on Globus Medical (GMED)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED – Get Rating).
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.